Literature DB >> 27517167

Hemodynamic Performance of Endovascular Valves as Valve-in-Valve in Small Stented Bioprosthesis.

Ralf-Uwe Kuehnel1, Martin Hartrumpf1, Michael Erb1, Johannes M Albes1.   

Abstract

Background Endovascular valve in stented biological valve implantation (valve-in-valve transcatheter aortic valve implantation [TAVI ViV]) is increasingly becoming a valid option for bioprosthesis degeneration. TAVI implantation in small stented biological valves below 23 mm is controversially discussed. Reduced opening area and high gradients are typical objections against this procedure in cases of small bioprosthesis. Systematic studies about the hemodynamic performance of endovascular valves in small stented bioprosthesis, however, do not exist. Methods Stented biological valves of 21 mm size were analyzed in a pulse duplicator (cardiac output 4.9 L/min). Edwards Perimount Magna (EP; Edwards Lifesciences, Irvine, California, United States), Medtronic Mosaic (MM; Medtronic Inc., Minneapolis, Minnesota, United States), and Sorin Mitroflow (SM; Milan, Italy) were investigated (three valves, each type). Mean transvalvular gradients were measured before and after implantation of Edwards Sapien 23 mm (SAP) as ViV. Results There were no marked differences of mean transvalvular gradients before and after ViV (EP21: 12.3 mm Hg; EP21 + SAP: 11.1 mm Hg; SM21: 13.5 mm Hg; SM21 + SAP: 14.9 mm Hg; MM21: 21.4 mm Hg; MM21 + SAP: 15.1 mm Hg). MM valves fabricated from porcine cusps showed higher initial gradients in contrast to valves constructed with pericardium (EP and SM). After ViV, however, this difference was reduced. Conclusion This in vitro study shows that hemodynamic performance of endovascular valves as ViV in small bioprosthesis does not differ significantly from the performance of the initial implanted prosthesis. Hemodynamic performance of porcine cusp valves could even be optimized. It can thus be speculated that TAVI ViV also offers a reasonable option for patients with typical stented bioprosthetic degeneration to substantially prolong adequate function with one initial surgical and one consecutive interventional procedure even in small valves. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2016        PMID: 27517167     DOI: 10.1055/s-0036-1586492

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  2 in total

1.  Hemodynamic outcomes after valve-in-valve transcatheter aortic valve replacement: a single-center experience.

Authors:  R Yazan Kherallah; Srikanth Koneru; Zvonimir Krajcer; Ourania Preventza; Kathryn G Dougherty; Melissa L McCormack; Briana T Costello; Stephanie Coulter; Neil E Strickman; Juan Carlos Plana Gomez; Ali Mortazavi; Jose G Díez; James J Livesay; Joseph S Coselli; Guilherme V Silva
Journal:  Ann Cardiothorac Surg       Date:  2021-09

2.  Haemodynamic outcomes following aortic valve-in-valve procedure.

Authors:  Anne-Sophie Zenses; Abdellaziz Dahou; Erwan Salaun; Marie-Annick Clavel; Josep Rodés-Cabau; Géraldine Ong; Ezéquiel Guzzetti; Mélanie Côté; Robert De Larochellière; Jean-Michel Paradis; Daniel Doyle; Siamak Mohammadi; Éric Dumont; Chekrallah Chamandi; Tania Rodriguez-Gabella; Régis Rieu; Philippe Pibarot
Journal:  Open Heart       Date:  2018-07-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.